Characterizing the role of SLC3A2 in the molecular landscape and immune microenvironment across human tumors

SLC7A11/GPX4 Inactivation-Mediated Ferroptosis Contributes to the Pathogenesis of Triptolide-Induced Cardiotoxicity

(2022) Xian Liu et al.   Oxidative Medicine and Cellular Longevity

Cancer cells dying from ferroptosis impede dendritic cell-mediated anti-tumor immunity

(2022) Bartosz Wiernicki et al.   Nature Communications

Targeting SLC3A2 subunit of system XC− is essential for m6A reader YTHDC2 to be an endogenous ferroptosis inducer in lung adenocarcinoma

(2021) Lifang Ma et al.   FREE RADICAL BIOLOGY AND MEDICINE

Immunotherapy using IgE or CAR T cells for cancers expressing the tumor antigen SLC3A2

(2021) Giulia Pellizzari et al.   Journal for ImmunoTherapy of Cancer

CAF secreted miR-522 suppresses ferroptosis and promotes acquired chemo-resistance in gastric cancer

(2020) Haiyang Zhang et al.   Molecular Cancer

The Role of Erastin in Ferroptosis and Its Prospects in Cancer Therapy

(2020) Yuechen Zhao et al.   OncoTargets and Therapy

Cystine transporter SLC7A11/xCT in cancer: ferroptosis, nutrient dependency, and cancer therapy

(2020) Pranavi Koppula et al.   Protein & Cell

Overexpression of membranal SLC3A2 regulates the proliferation of oral squamous cancer cells and affects the prognosis of oral cancer patients

(2020) Jiayu Liang et al.   JOURNAL OF ORAL PATHOLOGY & MEDICINE

Delivery technologies for cancer immunotherapy

(2019) Rachel S. Riley et al.   NATURE REVIEWS DRUG DISCOVERY

Targeting Ferroptosis to Iron Out Cancer

(2019) Behrouz Hassannia et al.   CANCER CELL

Drug delivery systems targeting tumor-associated fibroblasts for cancer immunotherapy

(2019) Mengrui Liu et al.   CANCER LETTERS

LncRNA SNHG1 contributes to sorafenib resistance by activating the Akt pathway and is positively regulated by miR-21 in hepatocellular carcinoma cells

(2019) Weidong Li et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

Radiotherapy and immunotherapy promote tumoral lipid oxidation and ferroptosis via synergistic repression of SLC7A11

(2019) Xueting Lang et al.   Cancer Discovery

The Immune Landscape of Cancer

(2018) Vésteinn Thorsson et al.   IMMUNITY

Dual targeting of ErbB2/ErbB3 for treatment of SLC3A2-NRG1-mediated lung cancer

(2018) Dong Hoon Shin et al.   MOLECULAR CANCER THERAPEUTICS

Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

(2018) Freddie Bray et al.   CA-A CANCER JOURNAL FOR CLINICIANS

SLC3A2 is upregulated in human osteosarcoma and promotes tumor growth through the PI3K/Akt signaling pathway

(2017) Bin Zhu et al.   ONCOLOGY REPORTS

SLC3A2, antigen of mAb 3G9, promotes migration and invasion by upregulating of mucins in gastric cancer

(2017) Shanshan Wang et al.   Oncotarget

Slc3a2 Mediates Branched-Chain Amino-Acid-Dependent Maintenance of Regulatory T Cells

(2017) Kayo Ikeda et al.   Cell Reports

Pan-cancer Immunogenomic Analyses Reveal Genotype-Immunophenotype Relationships and Predictors of Response to Checkpoint Blockade

(2017) Pornpimol Charoentong et al.   Cell Reports

Simultaneous enumeration of cancer and immune cell types from bulk tumor gene expression data

(2017) Julien Racle et al.   eLife

Cancer immunotherapy targeting neoantigens

(2016) Yong-Chen Lu et al.   SEMINARS IN IMMUNOLOGY

Robust enumeration of cell subsets from tissue expression profiles

(2015) Aaron M Newman et al.   NATURE METHODS